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The advent of effective targeted therapeutics has led to increasing emphasis on precise biomarkers for accurate patient
stratification. Here, we describe the role of ACK1, a non-receptor tyrosine kinase in abrogating migration and invasion
in KRAS mutant lung adenocarcinoma. Bosutinib, which inhibits ACK1 at 2.7 nM IC50, was found to inhibit cell migration
and invasion but not viability in a panel of non-small cell lung cancer (NSCLC) cell lines. Knockdown of ACK1 abrogated
bosutinib-induced inhibition of cell migration and invasion specifically in KRAS mutant cells. This finding was further
confirmed in an in vivo zebrafish metastatic model. Tissue microarray data on 210 Singaporean lung adenocarcinomas
indicate that cytoplasmic ACK1 was significantly over-expressed relative to paired adjacent non-tumor tissue. Interestingly,
ACK1 expression in “normal” tissue adjacent to tumour, but not tumour, was independently associated with poor overall
and relapse-free survival. In conclusion, inhibition of ACK1 with bosutinib attenuates migration and invasion in the
context of KRAS mutant NSCLC and may fulfil a therapeutic niche through combinatorial treatment approaches.
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Lung cancer is the leading cause of cancer related death
world-wide [1]. It is estimated there will be ~228 190 new
lung cancer cases and ~159 480 lung cancer deaths in
the United States in 2012 (http://seer.cancer.gov/statfacts/
html/lungb.html). Although an increasing number of gen-
etic alterations in non-small cell lung cancer (NSCLC)
have become amenable to targeted therapeutics [2], an
emerging challenge is the identification of co-factors
that can modulate and attenuate intracellular signaling
cascades implicated in drug response or resistance–so
as to enable better patient selection and rational drug
combinations [3].
Activated Cdc42 associated kinase (ACK1) is a non-
receptor tyrosine kinase residing in the cytoplasm. The
kinase domain is located at the N-terminal half of the
protein followed by multiple protein-protein interaction* Correspondence: btchua@imcb.a-star.edu.sg
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stated.domains such as CRIB where Cdc42 binds [4]. The
C-terminal half of the protein interacts with partners
including clathrin, EGFR, ubiquitin, Nedd4 E3 ligase and
Grb2 [5-8]. Recent work by Mahajan et al. shows that
ACK1 phosphorylates AKT at Tyr 176, resulting in its
activation [9]. Several reports have implicated ACK1
over-expression and amplification in tumorigenesis of
different tissue types e.g. gastric, pancreatic and lung
[10,11]. High expression of phosphorylated ACK1 cor-
relates with disease progression in breast, prostate and
pancreatic cancers [12-14], with specific interactions
between the ACK1 kinase and key signaling nodes e.g.
androgen receptors in prostate cancer. In melanoma
cell lines, ACK1 is activated in response to integrin sig-
naling, resulting in cell spreading [15]. In vivo, ACK1
over-expressing cells resulted in aggressive metastatic
tumors [10,12] while in vitro silencing of the ACK1 gene
in RAS-transformed NIH3T3 cells increased apoptosis
[16]. Recently, we have also shown that silencing of ACK1
results in reduced ERK and AKT phosphorylation and
interestingly, EMT reversion [17].
We hypothesized that ACK1 hyperactivity through
over-expression influences metastatic potential in lung. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Bosutinib (SKI-606) is a third generation dual SRC-ABL
kinase inhibitor developed by Wyeth (Pfizer) that also binds
and prevents auto-phosphorylation of ACK1 at IC50 of
2.7 nM [18,19]. Our results show that bosutinib inhibited
cancer cell migration and invasion via ACK-1 in a KRAS
dependent manner – in both in vitro cell lines as well as
an in vivo zebrafish model. Further, we validated ACK1
protein expression in 210 lung adenocarcinoma tissue
microarrays using immunohistochemistry, where high
expression of tumor ACK1 was observed as compared
to paired adjacent “normal” lung tissue. Although tumor
ACK1 expression was not associated with survival out-
comes in resected NSCLC, intriguingly, ACK1 expression
in adjacent “normal” lung was associated with worse
overall and relapse-free survival in both univariate and
multivariate models.Results
Bosutinib inhibits KRAS mutant but not KRAS wild type
cell migration and invasion
We have previously demonstrated that ACK1 plays an
important role in cell migration and epithelial mesenych-
mal transition in both in vitro over-expression and gene
silencing systems [17]. We tested the effect of bosutinib
on cell migration in a panel of eight NSCLC cell lines that
migrate efficiently across the 8 μm transwell with 10% FBS
as a chemoattractant. We also tested the invasive potential
of the cell lines using Matrigel™ assay. As shown in Figure 1,
sub-lethal concentration (0.1, 0.5 and 1 μM) of bosutinib
were sufficient to inhibit cell migration and invasion in a
dose-dependent manner. Unexpectedly, this was only ob-
served in KRAS mutant cells as shown in Figure 1A and
C. In contrast, bosutinib had no effect on migration in 3
out of 4 KRAS wild type NSCLC cell lines (Figure 1B). In
addition, all 4 KRAS mutant cell lines showed reduced
migration in the invasion Matrigel assay, while two KRAS
WT cell lines tested were not inhibited by bosutinib
(Figure 1D).Effect of bosutinib on viability of NSCLC cell lines is
independent of KRAS status
Across the panel of NSCLC lines, bosutinib reduced cell
viability at micromolar IC50 of between 1–5 μM (Figure 2A
and B) via apoptosis (Figure 2C) in all tested KRAS
mutant and KRAS wild type (WT) lung cancer cell lines.
Based on steady state (D15) dosing of bosutinib [MW
530.44616] in the clinic at 400 and 500 mg daily, Cmax
was 190 ng/mL and 273 ng/mL respectively, [20] ap-
proximately corresponding to in vitro concentrations
of 0.3 – 0.5 μM. Thus, clinically relevant doses of bosuti-
nib are able to inhibit migration and invasion but not
viability in NSCLC cell lines.Bosutinib inhibition of cell migration and invasion is
ACK1 dependent and SRC-independent
Since both SRC and ACK1 play a role in cell motility
[17,21-24] and bosutinib can inhibit both kinases, we
evaluated if one or both of these target kinases (ACK1
and SRC) were mediating the migratory effect. Using
NCI-H1792, a KRAS mutated NSCLC cell, we silenced
either ACK1 or SRC or both and measured migration
and invasion upon bosutinib treatment. Real time PCR
data (Figure 3A) showed that silencing of ACK1, SRC or
both effectively reduced the respective transcript levels.
Expectedly, with ACK1 or SRC knockdown, cell migration
and invasion was reduced ~50%, further consolidating the
role of these kinases in cell motility (Figure 3B & C). In
SRC-silenced cells, dose-dependent inhibition of cell mi-
gration and invasion was still observed after treatment
with increasing concentration of bosutinib. In contrast,
in ACK1 and ACK1/SRC dual-silenced cells, bosutinib-
induced inhibition of cell migration was abolished. The
same effect was also observed in a second KRAS mutant
NSCLC cell line, SK-Lu-1 (Additional file 1: Figure S1)
after treated with bosutinib. These data support the role of
ACK1 as a target of bosutinib in inhibiting cell migration
and invasion in KRAS mutant cell lines.
Reduction of lung cancer cell metastasis in zebrafish
embryos by bosutinib is ACK1 dependent
Next, we examined if in vitro migratory and invasive
inhibition by bosutinib could be translated into metastasis
inhibition in vivo. Zebrafish is a well-recognized model of
human malignancy due to conserved genetics and cell
biology [25]. Using zebrafish as the host organism, we
have developed a quantitative in vivo cell migration assay
to monitor the response of cells to anti-cancer agents.
Transparency of the embryos provides us with the unique
ability to visualize in vivo drug responses and migratory
changes of cancer cells in real time. Here we injected
boluses of fluorescently labeled human NCI-H2009 cells,
which were successfully transfected with siRNA against
ACK1, SRC or negative control (Additional file 2: Figure
S2), into the yolk sac of 24–30 h old embryos. The labeled
NCI-H2009 cells were observed to migrate out from the
injection site and metastasized to various parts of the em-
bryos (Figure 4A). To test the effect of bosutinib on these
metastatic cells in vivo, we pretreated the labeled cells
with bosutinib before injecting them into the embryos.
The metastatic potential of NCI-H2009 cells transfected
with control and SRC siRNA was significantly reduced after
pretreatment with low dose bosutinib (Figure 4A and B)
while such a significant reduction was not observed in
cells transfected with ACK1 siRNA (Figure 4C). These
observations further support the role of ACK1 as a target
of bosutinib in inhibiting cell migration and invasion in
KRAS mutant cell lines in vivo.
Figure 1 Bosutinib inhibit KRAS mutant cell migration and invasion but not KRAS wildtype cells. The serum-starved KRAS (A & C) mutant
and (B & D) wildtype cells were trypsinized and seeded in the upper chamber of the Transwell (8 mm pore, A & B) or Matrigel™ (C & D), in the
presence of DMSO or bosutinib at various concentrations (0.1, 0.5 and 1 μM). Medium containing 10% FBS and DMSO or bosutinib (0.1, 0.5 and
1 μM) was used as chemoattractant in the lower chamber. The migrated or invaded cells were fixed and stained with 0.5% crystal violet blue after
6 h and 24 h respectively. Cells that migrated or invaded across the filter were counted. Experiments were carried out in duplicates with five
random fields counted. The percentage of migrated or invaded cells was expressed with respect to the DMSO treated cells.
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In 2005, Van der Horst et al. [10] showed that the ACK1
gene is amplified in numerous cancer types including lung
cancers and this correlated with metastatic potential and
poor prognosis. Here, we validated the total protein ex-
pression of ACK1 using immunohistochemistry staining
on 210 lung adenocarcinoma on an in-house tissue
microarray (TMA). In comparison with surrounding paired
non-tumor lung sections, ACK1 is substantially and signifi-
cantly (all p < 0.001) over-expressed in tumor tissue across
immunohistochemisty summaries (including ACK1 max-
imum staining intensity, percentage staining, and IP). The
difference in IP score (see Immunohistochemistry section
in Method for definition) between tumour and adjacent
non-tumour lung tissue is illustrated in Figure 5.
ACK1 over-expression in adjacent “normal” lung tissue
portends poorer outcomes in lung adenocarcinoma
The ACK1 IHC data was subjected to statistical analysis.
Here, we found significant univariates that predicted for
overall and relapse-free survival were stage, grade, smoking
status, histology, and non-tumor ACK1 expression, as
shown in supplementary data, Additional file 3: Table S1.
Multivariate models were developed, adjusting for the
relationship between prognosis and the important clinical
covariates stage and grade, in the context of a Cox propor-
tional hazards model. Interestingly, ACK1 over-expressionin paired surrounding non-tumor “normal” tissue was in-
dependently associated with worse overall and relapse-free
survival, as shown in Table 1.
Discussion
In the era of molecularly-directed therapeutics in NSCLC,
there has been increasing interest in discovery of novel
biomarkers for improved patient stratification and treat-
ment. While EGFR mutant and ALK translocated NSCLC
have been successfully targeted in the clinic, KRAS muta-
tions account for 15-22% of cases and to date, there are no
clinically validated targeted therapies [2,26]. In this article,
we present novel data highlighting a potential therapeutic
role for bosutinib in abrogating migration and invasion in
KRAS mutant NSCLC cell lines through ACK1.
The unexpected observation of bosutinib-mediated at-
tenuation of migration and invasion specifically in KRAS
mutant cell lines underscores the importance of evaluating
targeted therapeutics in the appropriate genetic context.
Our experiments also reveal the potential for identifying
therapeutic niches beyond oncogenic drivers, where “off-
target” inhibition of selected kinases may confer desirable
anti-cancer effects other than reducing cell viability or
induction of apoptosis. Indeed, the induction of apoptosis
at bosutinib doses beyond 1 μM very likely involves non-
specific multi-kinase inhibition. In contrast, inhibition of
migration and invasion was observed at doses as low as
Figure 2 Effect of bosutinib on viability of NSCLC cell lines is independent of KRAS status. The KRAS mutant (A) and wildtype (B) NSCLC or
Normal Human Bronchial Epithelial (NHBE) cells were seeded onto 96-well plates for 24 h. The cells were treated with various concentrations
(0–10 μM) of bosutinib for 72 h followed by cell viability assay measured by CellTitre Glo. The cell viability results were normalized to DMSO-treated
controls and expressed in percentage. (C) Four NSCLC cells were treated with bosutinib for 72 h at different concentrations. Caspase3/7 activities were
measured using Caspase-Glo 3/7 luminescent assay kit. The enzymatic activity is expressed as the value with respect to untreated cells.
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kinase inhibition at clinically relevant doses (Cmax of
bosutinib at 400 mg daily is 190 ng/mL which is approxi-
mately 0.3 μM).
In this study, silencing of ACK1 or SRC alone signifi-
cantly reduced cell migration and invasion, confirming their
role in regulating metastasis. In addition, using bosutinib
at dose of 0.5 μM and 1 μM)) as a chemical probe, we
observed that the effect on migration and invasion were
abrogated only by knockdown of ACK1 and not SRC,
highlighting the importance of ACK1 in the signaling axis.
This is further supported by the zebrafish model, where
siRNA to ACK1 abrogated the anti-migratory effect of
bosutinib. Another previously reported interacting partner
of ACK1, AXL has been shown to regulate cell migration
and invasion in breast cancer. In our NSCLC panel, we
found that absence of AXL in NCI-H1792 had no effect
on bosutinib-induced inhibition in cell migration and
invasion (Additional file 4: Figure S3), suggesting that
contradistinct to breast cancer [27]. AXL may not play a
dominant role in the metastatic phenotype in NSCLC.
Furthermore, given that ACK1 can be activated by re-
ceptor tyrosine kinases such as EGFR and ALK [5,24],
bosutinib may have broader therapeutic relevance to
NSCLC.Separately, through the assembly of 210 tumors, we
created TMAs to examine the clinical relevance of ACK1
expression in NSCLC. Here we chose to focus on total
ACK1 expression and not phospho-ACK1 for two reasons.
First, we have shown previously that in cell lines over-
expression of wild type ACK1 plasmid resulted in ACK1
that is phosphorylated and active [17]. Secondly, the com-
mercial available phospho-ACK1 antibody is not optimized
for our TMAs, and artefactual dephosphorylation due to
inconsistencies in time to fixation of paraffin embedded
surgical samples may limit the accuracy of depicting intrin-
sic signaling activity [28,29]. In our cohort of 210 patients
with lung adenocarcinoma, there was a substantial and
significant difference in ACK1 protein expression between
non-tumor and tumor cores, consistent with its role in
tumorigenesis. However, we did not find a clear inverse
association between tumor ACK1 over-expression and
survival, suggesting a more nuanced relationship to clinical
outcomes. It is possible that majority of tumours on the
TMA were stage I, where ACK1 expression may have less
impact on clinical outcome. In later stage tumours, given
the central role of ACK1 in migration and invasion, any
increase in protein expression, regardless of extent, can
be deleterious – thus mitigating any correlation between
intensity percentage and patient outcomes. Intriguingly,
Figure 3 Bosutinib inhibit cell migration and invasion is ACK1
dependent and SRC- independent. NCI-H1792 were transfected with
siRNA (control, ACK1 or SRC) using Oligofectamine for 72 h. The cells
were harvested at 72 h. (A) Quantitative real-time PCR analysis was
performed using 20 ng of cDNA and respective primers set for ack1 and
src and normalized to gapdh. The serum-starved cells were trypsinized
and seeded in upper chamber of the Transwell (8 mm pore, B) or
Matrigel™ (C), in the presence of DMSO or bosutinib at various
concentrations (0.5 and 1 μM). Medium containing 10% FBS and DMSO
or bosutinib (0.5 and 1 μM) was used as chemoattractant in the lower
chamber. The cells were fixed and stained with 0.5% crystal violet blue
after 6 h (migration, B) and 24 h (invasion, C). Cells that migrated or
invaded across the filter were counted. Experiments were carried out
in duplicates with five random fields counted.
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“normal” lung tissue was associated with poor outcome,
suggesting that ACK1 activation may be an early event
in lung cancer carcinogenesis.
Another interesting observation arising in this study is
the relationship between KRAS, ACK1 and cell migration,
invasion and EMT. To date, there is no direct connection
between the two proteins, with exception to the publication
by Nur et al. [16]. Their work and ours suggested ACK1 is
an important pro-oncogenic factor downstream of constitu-
tive active RAS, probably also mediating EMT. Consistent
with this notion, numerous reports have suggested that
RAS activation by TGF signaling results in upregulation
of 2 transcription factors, snail and snug, which repress
E-cadherin and induce EMT [30-32]. Our preliminary
analysis of twist, a mesenchymal transcription factor using
real time PCR on our panel of NSCLC lines showed differ-
ential high and low twist mRNA in RAS mutant and WT
cell lines respectively (data not shown). From this panel of
cell lines, preliminary data suggests that RAS-driven EMT
and migratory signals are mediated through ACK1.
Recently, the phase I study of bosutinib, including an
expansion cohort in colon, lung and pancreatic cancer,
was reported [20]. Although no objective tumor responses
were recorded and the trial did not meet predetermined
efficacy endpoints, stable disease was observed in 47% of
NSCLC patients (n = 19), with 16% of patients with dur-
able disease control of more than 24 weeks. Regrettably,
KRAS and EGFR status were not reported in this study,
and it is plausible that high ACK1 expression may stratify
a subgroup of EGFR and KRAS mutant patients likely to
respond to bosutinib.
In conclusion, ACK1 inhibition affects cell motility and
migration particularly in the context of KRAS mutant
NSCLC cell lines, and is highly expressed in lung adeno-
carcinoma as compared to paired surrounding non-tumor
tissue. Given the implicated role of ACK-1 in EGFR, KRAS
and ALK signaling, we suggest a potential therapeutic
niche for combination studies with bosutinib selecting for
patients with ACK-1 overexpression, specifically in circum-
venting tumor metastasis and recurrence.
Materials and methods
Lung cancer cell lines
Human lung adenocarcinoma cell lines [NCI-H1650, NCI-
H1792, NCI-H1838, NCI-H1975, NCI-H2009, NCI-H2291,
NCI-H2444, HCC-95, HCC-193, EKVX and SK-Lu-1] were
provided by Max Planck Institute of Biochemistry and au-
thenticated using STR profiling by John Hopkins Fragment
Analysis Facility (April 2013). All cells were maintained in
Roswell Park Memorial Institute medium supplemented
with L-glutamine and 10% fetal bovine serum, except for
SK-Lu-1 cells which were maintained in Minimum Essen-
tial Medium with L-glutamine and 10% fetal bovine serum.
Figure 4 Reduction of lung cancer cell metastasis in zebrafish embryos by bosutinib is ACK1 dependent. Embryo injected with Vibrant DiD
labeled NCI-H2009 cells showing tumor foci burden determined by segmented red channel (upper) and scatter plot representation of cell
dissemination (bottom). Each data series represents one fish and number of injected embryos from 3 biological replicates is indicated (n). Comparative
inhibition of cell migration, as measured by Migration Index, between untreated and drug pretreated cells is represented as bar graph (right),
Mean ± SD. (A) Embryos injected with NCI-H2009 transfected with control siRNA. (B) Embryos injected with NCI-H2009 transfected with SRC
siRNA. (C) Embryos injected with NCI-H2009 transfected with ACK1 siRNA.
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purchased from Lonza (Basel, Switzerland), and cultured
in serum-free medium as described by Clonetics. All cells
were incubated in a 37°C incubator with 5% CO2.
Reagents
Bosutinib (SKI-606) was purchased from LC Laboratories
(Woburn, MA) and prepared in DMSO as 10 mM stock.
The compound was diluted to desired concentration in
culture medium (or DMSO) before treatment. Results
were separately validated with bosutinib, synthesized by
Vichem Chemie Research Ltd (Budapest, Hungary)
Protein extraction and Western blot analysis
Cells were lysed in lysis buffer (50 mM HEPES, 150 mM
NaCl, 1 mM EDTA, 10% Glycerin, 1% Triton X-100,
10 mM Sodium pyrophosphate, 10 mM sodium fluoride,
2 mM sodium orthovanadate, 1 mM phenylmethanesulfonylfluoride, 0.2 μg/ml Aprotinin) for 20 minutes at 4°C, and
protein concentration were measured using BCA protein
assay (Thermo Scientific, Rockford, IL). Protein samples
were subjected to SDS-PAGE and transferred onto polyvi-
nylidene difluoride membrane. Membranes were blocked
with 5% milk in PBST/TBST (0.1% Tween-20) and incu-
bated with the primary antibodies: anti-ACK1 (A-11)
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
β-actin-HRP, anti-GAPDH-HRP, and anti-SRC antibodies
(Cell Signaling Technology®, Beverly, MA). The secondary
antibodies were anti-mouse and anti-rabbit horseradish
peroxidase conjugated antibodies (GE Healthcare). Detec-
tion was performed using Immobilon Western Chemilu-
minescence HRP substrate (Millipore, Billerica, MA).
Cell viability assay
Cancer cell lines and NHBE cells were seeded onto 96-well
plates at 80% confluency (1000 to 5000 cells). Cells were
Figure 5 ACK1 is highly expressed in lung adenocarcinoma. Immunohistochemistry staining was performed on 210 NSCLC tumor and paired
non-tumor sections on an in-house TMA using anti-ACK1 (C20, see material and method). (A) ACK1 immuno-positivity was defined as presence
of brown cytoplasmic staining. Staining intensity was scored as 0, 1+, 2+ and 3+ (no, weak, moderate and strong staining, respectively). (B)
Percentage of positively stained tumor cells was assessed as proportion of total number of tumor cells present in the section. Intensity percentage
score, IP, was defined as product of the maximum immunostaining intensity and percentage of tumor cells stained.
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Cell viability was measured using CellTiter-Glo reagent
(Promega, Madison, WI) according to manufacturer’s
instructions. Cell viability results were normalized to
DMSO-treated controls and expressed in percentage.
Apoptotic assay
Cells were seeded onto 96-well plates at 80% confluency
overnight (1000–5000 cells) and treated with Bosutinib at
various concentrations for 72 h. Apoptosis was measured
using Caspase-Glo® 3/7 luminescent assay according to
manufacturer’s instructions (Promega Corp., Madison, WI).
Caspase activity was expressed in percentage with DMSO
treated cells set as 100%.
Migration and invasion assay
Serum-starved cells (50000 to 100000) were suspended in
200 μL of serum-free medium and treated with Bosutinib
(0.1, 0.5 and 1 μM) or DMSO control. Cells were loadedTable 1 Unique relationship* between overall and relapse-free
Overall survival
Tumor ACK 1 IP p = 0.982 (overall) (per 10 units) 0.999 (0.9
Non-tumor ACK 1 IP p < 0.001 (overall) (per 10 units) 2.002 (1.3
*Adjusted for stage and grade.into each 8.0 μm pore polycarbonate membrane insert
(Corning, Inc., Corning, NY), in duplicates. Cell migrated
towards the lower chamber containing 600 μL of medium
with 10% FBS and DMSO or Bosutinib (0.1, 0.5 and
1 μM) for 6 h. This is followed by fixation and staining with
0.5% crystal violet blue in 25% methanol. Non-migrating
cells were removed with cotton swab and migrated cells
were counted in five random microscopic fields. Invasion
assay was performed as migration assay by replacing
the transwell with Matrigel™ transwells (Corning, Inc.,
Corning, NY).
siRNA silencing
Cells were seeded onto 24-well plate and transfected
with siRNA against ACK1 (#103419), SRC (#683), or nega-
tive control (Ambion, Austin, TX) using Oligofectatmine™
transfection reagent (Invitrogen, Carlsbad, CA) as described
in manufacturer’s protocol. Cells were collected for use at
72 h after transfection.survival and the ACK1 IP in tumor and non-tumor tissues
Relapse-free survival
30-1.074) p = 0.719 (overall) (per 10 units) 0.987 (0.916-1.062)
70-2.927) p < 0.001 (overall) (per 10 units) 1.907 (1.328-2.737)
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Total RNA was extracted and purified using RNeasy
Mini Kit (Qiagen, Germantown, MD). Superscript™ III
First-strand synthesis kit ((Invitrogen, Carlsbad, CA)
was used for reverse transcription under manufacturer’s
recommended conditions. Real-time PCR from the cDNA
product was performed with Applied Biosystems’s 7500
Fast real-time PCR system (Foster City, CA). Primers
specific to ACK1, SRC and GAPDH were used together
with Fast SYBR® green master mix (Applied Biosystems,
Foster City, CA) for PCR amplification under manufac-
turer’s conditions.
Zebrafish metastasis model
The zebrafish metastasis model (Zgraft) was developed with
approved protocols from both the Wayne State University
Institutional Animal Care and Use Committee (USA)
and the University of Windsor Animal Care Committee,
Canadian Council on Animal Care. Embryos were obtained
from natural spawnings of an AB strain. Developmental
stages are reported as hours post-fertilization (hpf) at 28°C.
NCI-H2009 tumor cells, transfected with siRNA against
ACK1, SRC, or negative control, were each cultured at 37°C
to 80% confluency, detached using Trypsin-EDTA solution
(Sigma), washed twice with DPBS (Gibco, Invitrogen) and
further incubated for 20 min at 37°C in serum free culture
media containing 0.05% DiD (Vibrant, Invitrogen). After an
incubation of 20 min, cells were washed twice and further
incubated for 5 h in media containing 0.25 μM bosutinib.
Cells were washed twice and re-suspended in DPBS for in-
jection. 24–30 hpf zebrafish embryos were dechorionated
and anesthetized with tricaine (Sigma). Using Nanoject II
(Drummond) injector, 200 cells were injected into the yolk
of each embryo. After injection, embryos were incubated
for 2 h at 31°C and checked for successful injection. Em-
bryos with fluorescent cells outside the yolk sack were
excluded from further experimentation and analysis.
Injected embryos were transferred to a 96-well plate
(one embryo/well) containing Bosutinib (0.25 μM) diluted
in 200 ml E3 media (without methylene blue) and further
incubated at 35°C for 46 h. Control embryos without drug
were treated and incubated in the diluent (DMSO).
Quantification of cellular migration and metastasis
in zebrafish
Cellular migration and metastasis of xenotransplanted
tumor cells in zebrafish embryos is greatly influenced by
the number of cells injected, cell survival during drug
treatment, and the time of incubation post injection. For
consistent quantitative comparison of cellular migration
between different tumor cell lines and different drug treat-
ments, a Migration Index is calculated from the analysis
performed through microscopic imaging. Embryos are
anesthetized on a microscope slide at 48 h post injectionand drug treatment and imaged using confocal fluorescence
microscope (Olympus, FV1200). Multiple Z plane images
are taken of each embryo and composite images are made
using ImageJ software. All composite images are gathered,
aligned to a specific orientation, and analyzed as a scatter
plot to determine tumor foci position relative to injection
site (0,0 on graph). Number of metastatic tumor cell foci
positions was calculated by applying a minimum area filter
to exclude unanchored migrating single cells. Axes rep-
resent the distance (μm) from the injection site. Cumu-
lative distance (CD) traveled by metastatic tumor cell foci
(in μm) was therefore calculated from the graph as the
sum of distances of all identified tumor foci from the
injection point in a single embryo.
Migration Index = 1/n ∑(CD at 48 h/Total number of
viable cells at 48 h) where n is the number of embryos
considered in the experiment.
To quantify the surviving tumor cells in zebrafish larvae,
zebrafish embryos were incubated in 50 μl protease
solution (2 units/ml collagenase (Roche) and 60 units/ml
dispase (Roche) in DMEM for 2 h at 37°C. Cells were
gently dispersed with pipetting to dissociate transplanted
embryo to a single cell suspension. 50 μl of 8% parafor-
maldehyde solution was added directly to the wells to fix
and count the fluorescent cells.
Clinical data
Cases of resected lung adenocarcinoma over a 10 years
period were retrieved from the lung cancer database
maintained in National Cancer Centre Singapore. Clinical
outcome data including overall and relapse-free survival
were collected from the database. This retrospective out-
come data was approved by the Singhealth ethics review
committee.
Construction of tissue microarray (TMA)
Paraffin embedded formalin fixed tissue blocks with paired
slides were retrieved and reviewed, and representative
tumor areas were selected for TMA construction. Selected
tumor samples were punched out from tissue blocks using
the Beecher microarrayer. Briefly, for each sample one
morphologically non-tumor area adjacent to the tumour
and four morphologically representative tumor areas were
defined based on haematoxylin and eosin (HE)-stained
sections. From each of these areas, a tissue cylinder was
punched out from the blocks and transferred into a recipi-
ent paraffin block. Each cylinder had diameter 2.0 mm.
Immunohistochemistry
4 mm sections were cut from TMA blocks and fished
onto coated slides (POLYSINE, Menzel-glaser) in a similar
orientation to facilitate evaluation. Sections were stained
with anti-ACK1 antibody using optimized protocols. Briefly,
paraffin sections of formalin-fixed tissue were stained for
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with 1:100 dilution. Sections were pretreated in citrate
buffer (pH 6.0) at 110°C for 15 minutes with a pressure
cooker. The staining was done with Dako Autostainer plus
(Dako Colorado, Inc., USA) with fully automated immuno-
histochemical staining and visualization by Dako REAL™
EnVision™ Detection System (K5007). A breast cancer
section was used as positive control according to antibody
data sheet.
Stained slides were scanned using ScanScope digital
scanners (Aperio, Vista, CA). Scanned slides were then
viewed and scored using the Aperio Image Scope to deter-
mine intensity of immunostaining. ACK1 immunopositiv-
ity was defined as presence of brown cytoplasmic staining.
Staining intensity was scored as 0, 1+, 2+ and 3+ (no, weak,
moderate and strong staining, respectively). Percentage of
positively stained tumor cells was assessed as proportion
of total number of tumor cells present in the section. In-
tensity percentage score (IP) were documented. Intensity
percentage score was defined as product of the maximum
immunostaining intensity and percentage of tumor cells
stained. Staining were scored independently by two certi-
fied pathologists (Dr Lim KH and Dr Takano A).Statistical analysis
Tumor and non-tumor ACK1 immunohistochemistry
measures were compared using paired t-tests. Overall
and relapse-free survival were compared in the context
of Cox proportional hazards models, both individually
and after adjusting for the important covariates stage and
grade. Analysis was performed on R statistical software.
Data from preclinical experiments were analysed and
presented using Graphpad Prism version 6.0c.Additional files
Additional file 1: Figure S1. Bosutinib inhibit cell migration and
invasion is ACK1 dependent and SRC independent. SK-Lu-1 were
transfected with various siRNA using Oligofectamines and harvested
at 72 h. (A) Quantitative real time PCR analysis was performed using
20 ng cDNA and respective primer set for ack1 and src normalized to
gapdh. The serum-starved cells were trysinized and seeded in the
upper chamber of the Transwells (8 μm pore, B) or MatrixgelTM(C), in
the presence of DMSO or 0.5 μM of bosutinib. Medium containing
10% FBS and DMSO or bosutinib (0.5 μM) was used as chemoattractant in
the lower chamber. Cells were fixed and stained with 0.5% crystal violet blue
after 6 h (migration, B) and 24 h (invasion, C). Cells that migrated across the
filter were counted. Experiments were carried out in duplicates with five
random fields counted.
Additional file 2: FigureS2. Real time PCR analysis of ACK1 or SRC.
NCI-H2009 were transfected with siRNA (control, ACK1 or SRC) using
Oligofectamine for 72 h. The cells were harvested at 72 h. Quantitative
real-time PCR analysis was performed using 20 ng of cDNA and respective
primers set for ack1 and src and normalized to gapdh.
Additional file 3: Table S1. Individual relationships between OS or RFS
and clinical variables as well as ACK1 measures in tumor and paired
non-tumor tissues.Additional file 4: Figure S3. Bosutinib inhibition of cell migration is
AXL independent. (A) 50 μg lysate protein was analyzed for total AXL protein
using Western blot. 500 μg of the individual lysate was immunoprecipitated
with anti-AXL (AF154) and immunoblot with antiphosphotyrosine (4G10).
The PVDF membrane were stripped and re-blotted with anti-AXL (C-20).
(B) NCI-H1792 was transfected with siRNA using Oligofectamine for 72 h.
The serum starved cells were trysinized and seeded in the upper chamber
of the Transwell (8 μm pore), in the presence of DMSO or bosutinib at
various concentrations. Medium containing 10% FBS and DMSO or bosutinib
was used as chemoattractant in the lower chamber. Cells were fixed and
stained with 0.5% crystal violet blue after 6 h. Cells that migrated across the
filter were counted. Experiments were carried out in duplicates with five
random fields counted. Knockdown was confirmed on western blot analysis
with 50 μg of the total protein on the right.
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